Link to the University of Pittsburgh Homepage
Link to the University Library System Homepage Link to the Contact Us Form

Oncolytic HSV Vectors and Anti-Tumor Immunity

Glorioso, Joseph C. and Cohen, Justus B. and Goins, William F. and Hall, Bonnie and Jackson, Joseph W. and Kohanbash, Gary and Amankulor, Nduka and Kaur, Balveen and Caligiuri, Michael A. and Chiocca, E. Antonio and Holland, Eric C. and Quéva, Christophe (2020) Oncolytic HSV Vectors and Anti-Tumor Immunity. Current Issues in Molecular Biology, 4 (1). pp. 381-468. ISSN 14673037

Published Version

Download (851kB) | Preview


The therapeutic promise of oncolytic viruses (OVs) rests on their ability to both selectively kill tumor cells and induce anti-tumor immunity. The potential of tumors to be recognized and eliminated by an effective anti-tumor immune response has been spurred on by the discovery that immune checkpoint inhibition can overcome tumor-specific cytotoxic T cell (CTL) exhaustion and provide durable responses in multiple tumor indications. OV-mediated tumor destruction is now recognized as a powerful means to assist in the development of anti-tumor immunity for two important reasons: (i) OVs, through the elicitation of an anti-viral response and the production of type I interferon, are potent stimulators of inflammation and can be armed with transgenes to further enhance anti-tumor immune responses; and (ii) lytic activity can promote the release of tumor-associated antigens (TAAs) and tumor neoantigens that function as in situ tumor-specific vaccines to elicit adaptive immunity. Oncolytic herpes simplex viruses (oHSVs) are among the most widely studied OVs for the treatment of solid malignancies, and Amgen's oHSV Imlygic® for the treatment of melanoma is the only OV approved in major markets. Here we describe important biological features of HSV that make it an attractive OV, clinical experience with HSV-based vectors, and strategies to increase applicability to cancer treatment.


Social Networking:
Share |


Item Type: Article
Status: Published
CreatorsEmailPitt UsernameORCID
Glorioso, Joseph C.glorioso@pitt.eduglorioso
Cohen, Justus B.jbc@pitt.edujbc
Goins, William;goins
Hall, Bonniebonnier@pitt.edubonnier
Jackson, Joseph W.
Amankulor, Ndukanma40@pitt.edunma40
Kaur, Balveen
Caligiuri, Michael A.
Chiocca, E. Antonio
Holland, Eric C.
Quéva, Christophe
Date: 17 September 2020
Date Type: Publication
Journal or Publication Title: Current Issues in Molecular Biology
Volume: 4
Number: 1
Publisher: MDPI AG
Page Range: pp. 381-468
DOI or Unique Handle: 10.21775/cimb.041.381
Schools and Programs: School of Medicine > Microbiology and Molecular Genetics
Refereed: Yes
ISSN: 14673037
Official URL:
Article Type: Review
Date Deposited: 27 Jul 2021 13:34
Last Modified: 27 Jul 2021 13:34


Monthly Views for the past 3 years

Plum Analytics

Actions (login required)

View Item View Item